These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 17485497)

  • 1. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.
    Chen L; Sabo JP; Philip E; Mao Y; Norris SH; MacGregor TR; Wruck JM; Garfinkel S; Castles M; Brinkman A; Valdez H
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2436-44. PubMed ID: 17485497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.
    MacGregor TR; Sabo JP; Norris SH; Johnson P; Galitz L; McCallister S
    HIV Clin Trials; 2004; 5(6):371-82. PubMed ID: 15682350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biotransformation and mass balance of tipranavir, a nonpeptidic protease inhibitor, when co-administered with ritonavir in Sprague-Dawley rats.
    Macha S; Chen L; Norris SH; Philip E; Mao Y; Silverstein H; Struble C; Beers W
    J Pharm Pharmacol; 2007 Sep; 59(9):1223-33. PubMed ID: 17883893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers.
    Garraffo R; Lavrut T; Ferrando S; Durant J; Rouyrre N; MacGregor TR; Sabo JP; Dellamonica P
    J Clin Pharmacol; 2011 Jul; 51(7):1071-8. PubMed ID: 21209236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.
    Li F; Wang L; Guo GL; Ma X
    Drug Metab Dispos; 2010 May; 38(5):871-8. PubMed ID: 20103582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring.
    Langmann P; Winzer R; Schirmer D; Heinz W; Leyh M; Guhl C; Weissbrich B; Klinker H
    Eur J Med Res; 2008 Oct; 13(10):469-71. PubMed ID: 19008174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).
    Walmsley SL; Katlama C; Lazzarin A; Arestéh K; Pierone G; Blick G; Johnson M; Meier U; MacGregor TR; Leith JG
    J Acquir Immune Defic Syndr; 2008 Apr; 47(4):429-40. PubMed ID: 18176328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients.
    McCallister S; Valdez H; Curry K; MacGregor T; Borin M; Freimuth W; Wang Y; Mayers DL
    J Acquir Immune Defic Syndr; 2004 Apr; 35(4):376-82. PubMed ID: 15097154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tipranavir: a novel nonpeptidic protease inhibitor of HIV.
    King JR; Acosta EP
    Clin Pharmacokinet; 2006; 45(7):665-82. PubMed ID: 16802849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers.
    la Porte CJ; Sabo JP; Béïque L; Cameron DW
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4840-4. PubMed ID: 19721063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.
    Goebel FD; MacGregor TR; Sabo JP; Castles M; Johnson PA; Legg D; McCallister S
    HIV Clin Trials; 2010; 11(1):28-38. PubMed ID: 20400409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.
    Gathe JC; Pierone G; Piliero P; Arasteh K; Rubio R; Lalonde RG; Cooper D; Lazzarin A; Kohlbrenner VM; Dohnanyi C; Sabo J; Mayers D
    AIDS Res Hum Retroviruses; 2007 Feb; 23(2):216-23. PubMed ID: 17263650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir.
    Huang F; Drda K; MacGregor TR; Scherer J; Rowland L; Nguyen T; Ballow C; Castles M; Robinson P
    Antimicrob Agents Chemother; 2009 Jan; 53(1):95-103. PubMed ID: 18955519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring.
    Morello J; Rodríguez-Novoa S; Blanco F; Vispo E; Barreiro P; Gonzalez-Pardo G; Jiménez-Nácher I; González-Lahoz J; Soriano V
    Ther Drug Monit; 2010 Apr; 32(2):242-4. PubMed ID: 20216112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers.
    Mukwaya G; MacGregor T; Hoelscher D; Heming T; Legg D; Kavanaugh K; Johnson P; Sabo JP; McCallister S
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4903-10. PubMed ID: 16304151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.
    Salazar JC; Cahn P; Yogev R; Negra MD; Castelli-Gattinara G; Fortuny C; Flynn PM; Giaquinto C; Ruan PK; Smith ME; Mikl J; Jelaska A;
    AIDS; 2008 Sep; 22(14):1789-98. PubMed ID: 18753862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.
    Denissen JF; Grabowski BA; Johnson MK; Buko AM; Kempf DJ; Thomas SB; Surber BW
    Drug Metab Dispos; 1997 Apr; 25(4):489-501. PubMed ID: 9107549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir.
    Moltó J; Valle M; Santos JR; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Clotet B
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1191-6. PubMed ID: 20860529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Morelló J; Garcia-Gascó P; Rodríguez-Novoa S; Soriano V
    Expert Opin Pharmacother; 2007 Apr; 8(6):839-50. PubMed ID: 17425479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.